2024-03-14 11:57:11 ET
Agenus Inc. (AGEN)
Q4 2023 Results Conference Call
March 14, 2024 08:30 AM ET
Company Participants
Zack Armen - Head of Investor Relations
Garo Armen - Chairman and Chief Executive Officer
Steven O'Day - Chief Medical Officer
Christine Klaskin - VP, Finance and Principal Financial and Accounting Officer
Todd Yancy - Chief Strategic Advisor
Conference Call Participants
Emily Bodnar - H.C. Wainright
Mayank Mamtani - B. Riley Securities
Colleen Kusy - Baird
Matthew Phipps - William Blair
Presentation
Operator
Good morning. My name is Audra, and I will be your conference operator today. At this time, I would like to welcome everyone to the Agenus Inc. Fourth Quarter and Full-Year 2023 Results Conference Call. Today's conference is being recorded. All lines have been placed on mute to prevent any background noise. After the speakers’ remarks, there will be a question-and-answer session. [Operator Instructions] At this time, I would like to turn the conference over to Zack Armen, Head of Investor Relations. Please go ahead.
Zack Armen
Thank you, Audra, and thank you all for joining us today. Today's call is being webcast and will be available on our website for replay. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans and timelines, as well as timelines for data release and partnership opportunities among other updates. These statements are subjects to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks.
Joining me today are Dr. Garo Armen, Chairman and Chief Executive Officer; Dr. Steven O'Day, Chief Medical Officer; and Christine Klaskin, Vice President of Finance. Dr. Robin Taylor, Chief Commercial Officer; and Dr. Todd Yancy, Chief Strategic Advisor, will be participating in the Q&A session.
Now, I'd like to turn the call over to Garo to highlight our progress in 2023 and to speak to our outlook for 2024. Garo?
Garo Armen
Thank you very much. Ladies and gentlemen, today it is with great enthusiasm that we gather to share the remarkable strides Agenus has made over the past year. Our journey has been marked by significant achievements, pivotal milestones and a steadfast commitment to innovation in the field of oncology....
Read the full article on Seeking Alpha
For further details see:
Agenus Inc. (AGEN) Q4 2023 Earnings Call Transcript